Michael D. Hogarty

18.0k total citations · 3 hit papers
110 papers, 6.9k citations indexed

About

Michael D. Hogarty is a scholar working on Neurology, Molecular Biology and Cancer Research. According to data from OpenAlex, Michael D. Hogarty has authored 110 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Neurology, 58 papers in Molecular Biology and 35 papers in Cancer Research. Recurrent topics in Michael D. Hogarty's work include Neuroblastoma Research and Treatments (95 papers), Cancer, Hypoxia, and Metabolism (34 papers) and Cell death mechanisms and regulation (20 papers). Michael D. Hogarty is often cited by papers focused on Neuroblastoma Research and Treatments (95 papers), Cancer, Hypoxia, and Metabolism (34 papers) and Cell death mechanisms and regulation (20 papers). Michael D. Hogarty collaborates with scholars based in United States, Canada and Australia. Michael D. Hogarty's co-authors include John M. Maris, Susan L. Cohn, Rochelle Bagatell, Wendy B. London, Garrett M. Brodeur, Xueyuan Liu, Julie R. Park, Peter S. White, Arlene Naranjo and Paul M. Thompson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

In The Last Decade

Michael D. Hogarty

104 papers receiving 6.8k citations

Hit Papers

Neuroblastoma 2007 2026 2013 2019 2007 2021 2019 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neuroblastoma
    2007 1.6k citations John M. Maris, Michael D. Hogarty et al. profile →
  2. Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group
    2021 249 citations Meredith S. Irwin, Arlene Naranjo et al. Journal of Clinical Oncology profile →
  3. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma
    2019 214 citations Julie R. Park, Susan G. Kreissman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael D. Hogarty United States 42 4.7k 3.9k 2.3k 1.5k 593 110 6.9k
Johannes H. Schulte Germany 42 2.1k 0.4× 4.3k 1.1× 2.1k 0.9× 1.3k 0.9× 437 0.7× 176 6.3k
Meredith S. Irwin Canada 43 1.9k 0.4× 4.2k 1.1× 1.5k 0.7× 3.1k 2.1× 381 0.6× 124 6.7k
Olaf Witt Germany 40 1.1k 0.2× 4.6k 1.2× 628 0.3× 1.6k 1.1× 378 0.6× 163 6.7k
Svetlana Pack United States 47 578 0.1× 3.1k 0.8× 1.1k 0.5× 1.5k 1.1× 1.1k 1.9× 130 6.5k
Takehiko Kamijo Japan 37 552 0.1× 5.1k 1.3× 1.0k 0.4× 3.2k 2.2× 462 0.8× 114 7.1k
Hedwig E. Deubzer Germany 31 734 0.2× 2.9k 0.8× 545 0.2× 1.1k 0.8× 180 0.3× 64 3.7k
Martin van der Valk Netherlands 33 382 0.1× 4.0k 1.0× 703 0.3× 3.6k 2.5× 820 1.4× 45 6.9k
Elizabeth W. Newcomb United States 43 382 0.1× 3.4k 0.9× 1.5k 0.6× 2.6k 1.8× 578 1.0× 81 6.5k
Thomas G. P. Grünewald Germany 37 367 0.1× 2.7k 0.7× 1.1k 0.5× 1.0k 0.7× 279 0.5× 103 4.4k
Sirpa Leppä Finland 36 520 0.1× 1.9k 0.5× 621 0.3× 1.8k 1.2× 161 0.3× 177 4.7k

Countries citing papers authored by Michael D. Hogarty

Since Specialization
Citations

This map shows the geographic impact of Michael D. Hogarty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael D. Hogarty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael D. Hogarty more than expected).

Fields of papers citing papers by Michael D. Hogarty

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael D. Hogarty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael D. Hogarty. The network helps show where Michael D. Hogarty may publish in the future.

Co-authorship network of co-authors of Michael D. Hogarty

This figure shows the co-authorship network connecting the top 25 collaborators of Michael D. Hogarty. A scholar is included among the top collaborators of Michael D. Hogarty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael D. Hogarty. Michael D. Hogarty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Brown, Erin G., E. Stanton Adkins, Peter Mattei, et al.. (2024). Evaluation of Image-Defined Risk Factor (IDRF) Assessment in Patients With Intermediate-risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. Journal of Pediatric Surgery. 60(1). 161896–161896. 1 indexed citations
3.
4.
Leck, Lionel, et al.. (2023). Mitoribosomal synthetic lethality overcomes multidrug resistance in MYC-driven neuroblastoma. Cell Death and Disease. 14(11). 747–747. 5 indexed citations
5.
Wolpaw, Adam J., Patricia Brafford, Guillem Pascual‐Pasto, et al.. (2022). Epigenetic state determines inflammatory sensing in neuroblastoma. Proceedings of the National Academy of Sciences. 119(6). 28 indexed citations
6.
Zöllner, Stefan, Saravana P. Selvanathan, Garrett T. Graham, et al.. (2017). Inhibition of the oncogenic fusion protein EWS-FLI1 causes G 2 -M cell cycle arrest and enhanced vincristine sensitivity in Ewing’s sarcoma. Science Signaling. 10(499). 46 indexed citations
7.
Campbell, Kevin, Julie M. Gastier‐Foster, Arlene Naranjo, et al.. (2017). Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Cancer. 123(21). 4224–4235. 95 indexed citations
8.
Evageliou, Nicholas F., Michelle Haber, Annette Vu, et al.. (2016). Polyamine Antagonist Therapies Inhibit Neuroblastoma Initiation and Progression. Clinical Cancer Research. 22(17). 4391–4404. 64 indexed citations
9.
Goldsmith, Kelly C., Xueyuan Liu, Annette Vu, et al.. (2012). Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma. Cancer Research. 72(10). 2565–2577. 62 indexed citations
10.
Gamble, Laura D., Michael D. Hogarty, Xueyuan Liu, et al.. (2012). Polyamine pathway inhibition as a novel therapeutic approach to treating neuroblastoma. SHILAP Revista de lepidopterología. 2. 162–162. 47 indexed citations
11.
Chayka, Olesya, Daisy Corvetta, Michael Dews, et al.. (2009). Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. JNCI Journal of the National Cancer Institute. 101(9). 663–677. 68 indexed citations
12.
London, Wendy B., Arlene Naranjo, Michael D. Hogarty, et al.. (2009). Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. Pediatric Blood & Cancer. 53(4). 563–569. 55 indexed citations
13.
Lestini, Brian, Kelly C. Goldsmith, Mark Fluchel, et al.. (2009). Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biology & Therapy. 8(16). 1587–1595. 76 indexed citations
14.
Goldsmith, Kelly C., et al.. (2009). BH3 response profiles from neuroblastoma mitochondria predict activity of small molecule Bcl-2 family antagonists. Cell Death and Differentiation. 17(5). 872–882. 45 indexed citations
15.
Mazánek, Pavel, Vincent van Dam, Huaqing Zhao, et al.. (2007). Deregulated Wnt/β-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene. 27(10). 1478–1488. 91 indexed citations
16.
Coughlin, Christina, Mark D. Fleming, Richard G. Carroll, et al.. (2006). Immunosurveillance and Survivin-Specific T-Cell Immunity in Children With High-Risk Neuroblastoma. Journal of Clinical Oncology. 24(36). 5725–5734. 73 indexed citations
17.
Mahoney, Nicholas R., et al.. (2006). Pediatric Horner Syndrome: Etiologies and Roles of Imaging and Urine Studies to Detect Neuroblastoma and Other Responsible Mass Lesions. American Journal of Ophthalmology. 142(4). 651–659.e2. 84 indexed citations
18.
Hogarty, Michael D., Cynthia Winter, Xueyuan Liu, et al.. (2002). No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.. PubMed. 62(22). 6481–4. 4 indexed citations
19.
Weiss, Matthew J., Chun Guo, Suzanne Shusterman, et al.. (2000). Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. Medical and Pediatric Oncology. 35(6). 526–530. 21 indexed citations
20.
Bagarazzi, Mark L., et al.. (1996). Pulmonary Mycobacterium gordonae Infection in a Two-Year-Old Child: Case Report. Clinical Infectious Diseases. 22(6). 1124–1125. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Johannes H. Schulte Breakdown of academic impact, for papers by Meredith S. Irwin Breakdown of academic impact, for papers by Olaf Witt Breakdown of academic impact, for papers by Svetlana Pack Breakdown of academic impact, for papers by Takehiko Kamijo Breakdown of academic impact, for papers by Hedwig E. Deubzer Breakdown of academic impact, for papers by Martin van der Valk Breakdown of academic impact, for papers by Elizabeth W. Newcomb Breakdown of academic impact, for papers by Thomas G. P. Grünewald Breakdown of academic impact, for papers by Sirpa Leppä
Rankless by CCL
2026